Skip to main content
Publications
Toback S, Hollis K, Beyhaghi H, Ziemiecki R, Odom D, Choi JM, Layton JB, Odak S, Jackson L, Williams V, Marchese AM, Milller A, Rousculp M. Presenteeism: the reality to be discussed with COVID-19 vaccine recipients. Poster presented at the European Scientific Working Group on Influenza (ESWI); September 17, 2023. Valencia, Spain.
Rousculp M, Beyhaghi H, Hollis K, Ziemiecki R, Layton JB, Odak S, Jackson L, Odom D, Williams V, Choi JM, Montazeri M, Marchese AM, Toback S. Burden and impact of reactogenicity among United States and Canadian adults receiving COVID-19 vaccines: Vaccine Impact on Productivity (VIP) Study. Poster presented at the European Scientific Working Group on Influenza (ESWI); September 17, 2023. Valencia, Spain.
Richardson D, Zhan L, Reynolds M, Odom D, Hollis K, Mitra D, McRoy L, Hargis J. The impact of advanced or metastatic breast cancer or its treatment on productivity, energy, and physical activity among palbociclib participants of the MADELINE Study. Poster presented at the Virtual 12th European Breast Cancer Conference; October 2, 2020.
Richardson D, Zhan L, Reynolds M, Hollis K, McRoy L, Mitra D, Mahtani R. Trends in daily mood, pain, and fatigue among participants in the MADELINE study. Poster presented at the 2019 San Antonio Breast Cancer Symposium; December 11, 2019. San Antonio, TX.
Gimenez-Arnau A, Abuzakouk M, Balp M-M, Berard F, Canonica GW, Grattan C, Hollis K, Hunter S, Khalil S, Knulst AC, Lacour J-P, Lynde C, Marsland A, McBride D, Nakonechna A, Ortiz De Frutoz FJ, Oude Elberink JNG, Sussman G, Tian H, Weller K, Maurer M. Economic and humanistic burden associated with angioedema in patients with chronic spontaneous/idiopathic urticaria. Poster presented at the EAACI Congress 2017; June 20, 2017. Helsinki, Finland.
Proctor C, McBride D, Balp M-M, McLeod L, Hunter S, Tian H, Khalil S, Hollis K, Maurer M. Comparison of twice-daily and once-daily Urticaria Activity Score: results from the first international burden of illness ASSURE-CSU study in inadequately-controlled chronic spontaneous (idiopathic) urticaria. Poster presented at the 25th European Academy of Dermatology and Venereology Congress; September 28, 2016. Vienna, Austria.
McBride D, Chambenoit O, Chiva-Razavi S, Lynde C, Sussman G, Chapman-Roth N, Weller K, Maurer M, Koenders J, Knulst AC, Elberink JN, Halliday A, Alexopoulos ST, Nakonechna A, Abouzakouk M, Sweeney C, Radder C, Wolin D, Hollis K, Tian H, Balp MM, Grattan C. First real-world study assessing health utility values for chronic spontaneous/idiopathic urticaria using the EQ-5D. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
Balp MM, Chambenoit O, Chiva-Razavi S, Lynde C, Sussman G, Chapman-Rothe N, Weller K, Maurer M, Koenders J, Knulst AC, Halliday A, Alexopoulos ST, Nakonechna A, Grattan C, Abouzakouk M, Sweeney C, Radder C, Wolin D, McBride D, Hollis K, Tian H, Elberink JN. Work productivity and activity impairment among chronic spontaneous/idiopathic urticaria patients: results from the first international burden of illness study (ASSURE-CSU). Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
Tian H, Chambenoit O, Chiva-Razavi S, Lynde C, Sussman G, Chapman-Rothe N, Weller K, Koenders J, Knulst AC, Elberink JN, Halliday A, Alexopoulos ST, Nakonechna A, Grattan C, Abouzakouk M, Sweeney C, Radder C, Wolin D, McBride D, Hollis K, Balp MM, Maurer M. Healthcare resource utilisation among chronic spontaneous/idiopathic urticaria patients- findings from the first international burden of illness study (ASSURE-CSU). Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
Weller K, Grattan C, Abuzakouk M, Berard F, Sussman G, Lynde C, Canonica GW, Knulst A, Ortiz De Frutos J, Nakonechna A, Gimenez-Arnau A, Oude Elberink JNG, Balp MM, Khalil S, Tian H, Hollis K, Sweeney C, Radder C, McBride D, Maurer M. Patient profile from the first international burden of illness study in inadequately controlled chronic spontaneous urticaria: ASSURE-CSU. Poster presented at the 24th European Academy of Dermatology and Venereology (EADV) Congress; October 2015. Copenhagen, Denmark.
Sussman G, Lynde C, Kanani A, Hebert J, Chiva-Razavi S, Chambenoit O, Khalil S, Hollis KA, McBride DW, Westlund RE, Tian H, Balp MM. ASSURE-CSU preliminary Canadian results: redefining our understanding of the clinical characteristics of patients with CSU/CIU refractory to H1- antihistamines. Poster presented at the 23rd World Congress of Dermatology; June 9, 2015. Vancouver, Canada.
Sussman G, Grattan C, Lynde C, Abuzakouk M, Nakonechna A, Chiva-Razavi S, Halliday A, Chambenoit O, Hollis KA, McBride DW, Radder CN, Tian H, Balp MM. ASSURE-CSU preliminary UK and Canadian results: a characterisation of angioedema in patients with refractory CIU/CSU from the UK and Canada. Poster presented at the 23rd World Congress of Dermatology; June 9, 2015. Vancouver, Canada.
Grattan C, Balp MM, Halliday A, Abouzakouk M, Hollis KA, McBride DW, Westlund RE, Wolin DL, Tian H, Alexopoulos ST, Nakonechna A. ASSURE-CSU preliminary UK results: assessing the impact of CSU on absence from work and work productivity. Poster presented at the 23rd World Congress of Dermatology; June 9, 2015. Vancouver, Canada.
Sussman G, Maurer M, Weller K, Nakonechna A, Abouzakouk M, Hollis K, McBride D, Balp MM, Berard F, Gimenez-Arnau AM, Frutos JO, Canonica GW, Knulst AC, Grattan C. Assessment of economic and humanistic burden of refractory chronic spontaneous/idiopathic urticaria: study design of the first observational study, ASSURE-CSU. Poster presented at the American Academy of Dermatology Annual Meeting; March 20, 2015.
Nakonechna A, Balp MM, Halliday A, Alexopoulos ST, Abouzakouk M, Hollis KA, McBride DW, Westlund RE, Grattan C, Tian H. UK sub-analysis of the ASSURE-CSU study: demographic characteristics and health related quality of life in patients with chronic spontaneous urticaria. Poster presented at the 23rd Congress of the European Academy of Dermatology and Venereology; October 2014. Amsterdam, the Netherlands.